InRhythm™ – Inhaled Antiarrhythmic for PAF

A breath of fresh air for
Paroxysmal Atrial Fibrillation patients.

InRhythm™, a Patient-Administered, Inhaled Antiarrhythmic for Acute Treatment of Paroxysmal Atrial Fibrillation (PAF)

Atrial fibrillation (AF) is the most commonly encountered, sustained cardiac arrhythmia in clinical practice. The risk of developing AF increases with age and tends to be higher in males than in females. The disease presents a wide spectrum of symptoms and severity AND it is progressive. Its current global prevalence is around 34 million patients, which is expected to increase as the general population ages. Paroxysmal AF accounts for approximately 39% of all diagnosed prevalent cases of AF.

InRhythm, our lead product under development, is an inhaled therapy to treat symptomatic paroxysmal atrial fibrillation (PAF) using approved drugs via inhalation.

AtrialFibrillation-PAF
  • New Therapeutic Goals

  • 1. Patient-administered allowing for faster treatment, at work or home
    2. Therapy initiated sooner may reduce disabling symptoms, life interruption & more importantly long term heart damage
    3. Rapidly absorbed through the lung and delivered to the heart
    4. Targets regions in the heart where PAF starts
    5. Rapid onset and conversion to normal sinus rhythm

Learn More About PAF

About Paroxysmal Atrial Fibrillation (PAF)

Atrial fibrillation involves the two upper chambers (atria) of the heart. Its name comes from the fibrillating (i.e. quivering) of the heart muscles of the atria instead of a coordinated contraction.

Paroxysmal atrial fibrillation (PAF) is a type of AF where episodes terminate spontaneously in less than 7 days, usually in less than 24 hours. About 1 in 4 people with paroxysmal atrial fibrillation eventually develop the permanent form of the condition.

The causes of PAF aren’t always known. They can be similar to causes of chronic AF, although most people with PAF have normal hearts. People with PAF appear to be at just as high a risk of developing blood clots as those with chronic AF.

Common symptoms of PAF can include:

  • Racing heartbeat
  • A fluttering feeling in the chest
  • Chest pain or pressure
  • Feeling out of breath
  • Weakness or tiredness
  • Dizziness and sweating
  • Faintness or light-headedness

Meeting an Unmet Need:
The Global Prevalence of Atrial Fibrillation (AF),
Over 34 Million & Growing

Prevalence of Atrial Fibrillation and Flutter (per 100,000) by Region, 2010
Overall AF:

34M patients

PAF without structural heart disease:

~11 – 12M patients

PAF patients with multiple weekly episodes:

~1M patients

AF causes:

15 – 20% of all ischemic strokes

Atrial fibrillation remains a significant unmet medical need. Current therapeutic and interventional options are inadequate and the incidence of AF is projected to grow significantly over the coming years. It is currently treated either through pharmacological intervention with a combination of rhythm control, rate control and anticoagulation therapies; electrical cardioversion; and/or catheter ablation. PAF results in high direct and indirect costs including physician visits, ER visits and extended hospital stays, in addition to costs related to complications as a result of invasive procedures.

For more information about InCarda: